Liu, J.; Mu, W.; Gao, T.; Fang, Y.; Zhang, N.; Liu, Y.
CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma. Pharmaceutics 2023, 15, 426.
https://doi.org/10.3390/pharmaceutics15020426
AMA Style
Liu J, Mu W, Gao T, Fang Y, Zhang N, Liu Y.
CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma. Pharmaceutics. 2023; 15(2):426.
https://doi.org/10.3390/pharmaceutics15020426
Chicago/Turabian Style
Liu, Jinhu, Weiwei Mu, Tong Gao, Yuxiao Fang, Na Zhang, and Yongjun Liu.
2023. "CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma" Pharmaceutics 15, no. 2: 426.
https://doi.org/10.3390/pharmaceutics15020426
APA Style
Liu, J., Mu, W., Gao, T., Fang, Y., Zhang, N., & Liu, Y.
(2023). CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma. Pharmaceutics, 15(2), 426.
https://doi.org/10.3390/pharmaceutics15020426